Page 3 - Phase Labs News Today

By Jeffrey T. Lewis ProPhase Labs said Thursday that its offer to buy certain assets from Navidea Biopharmaceuticals was rejected. Navidea "flatly" rejected...

ProPhase Labs (NASDAQ:PRPH – Get Rating) and ALX Oncology (NASDAQ:ALXO – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership. Profitability This table compares ProPhase Labs and ALX Oncology’s […]

ProPhase Labs (NASDAQ:PRPH – Get Rating) had its price objective decreased by HC Wainwright from $15.00 to $14.00 in a report released on Friday, The Fly reports. A number of other research firms also recently weighed in on PRPH. TheStreet raised shares of ProPhase Labs from a c rating to a b- rating in a […]

ProPhase Labs, Inc. (NASDAQ:PRPH – Get Rating) was the recipient of a significant growth in short interest in April. As of April 15th, there was short interest totalling 382,800 shares, a growth of 23.5% from the March 31st total of 309,900 shares. Based on an average daily volume of 45,200 shares, the days-to-cover ratio is […]

Garden City, NY, April 28, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next-generation biotech, genomics and diagnostics...

ProPhase Labs, Inc. (NASDAQ:PRPH – Get Rating) was the recipient of a significant growth in short interest in April. As of April 15th, there was short interest totalling 382,800 shares, a growth of 23.5% from the March 31st total of 309,900 shares. Based on an average trading volume of 45,200 shares, the days-to-cover ratio is […]

Disc Medicine Opco (NASDAQ:IRON – Get Rating) and ProPhase Labs (NASDAQ:PRPH – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, earnings, risk and institutional ownership. Institutional and Insider Ownership 75.4% of Disc Medicine […]

Disc Medicine Opco (NASDAQ:IRON – Get Rating) and ProPhase Labs (NASDAQ:PRPH – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and profitability. Volatility and Risk Disc Medicine Opco has a […]

GARDEN CITY, NY, Jan. 05, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a growth oriented and diversified diagnostics,...

Operator: Good morning, afternoon, evening, and welcome to the ProPhase Labs Third Quarter 2022 Financial Results Conference Call. All participants will be in listen-only mode.